
ABOUT NOVOTECH
Novotech is internationally recognized as the leading Asia Pacific-centered Biotech Contract Research Organization (CRO) with global execution capabilities.
Novotech is a clinical CRO with labs, phase I facilities, drug development consulting services, and FDA regulatory expertise and has experience in over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biotech clients conducting clinical trials in Asia Pacific, the US, and Europe. Novotech has over 3000 staff globally and 34 office locations.
SERVICES
-
Take advantage of the world’s fastest-growing clinical trials region to accelerate your global clinical development.
-
Delivering accurate, high-quality and timely biostatistics in clinical trials services, including statistical planning, analysis and reporting.
-
Novotech relies on years of experience, in-country knowledge and real-life big data to identify and propose the best-performing sites for your study.
-
Novotech’s Medical and Regulatory Consulting team offers full range of pre-clinical, regulatory affairs support, medical and pharmacovigilance consulting services.
-
Get streamlined and integrated clinical trial services delivered by a dedicated team of professionals with deep industry and therapeutic area expertise across all phases of clinical development.
WEBINARS
-
Hear from a panel of life science experts about the most recent developments and ground-breaking approaches shaping the field of vaccine development worldwide.
-
The webinar features regulatory affairs and investment leaders from North America and Asia Pacific who will discuss why biotech companies are increasingly exploring clinical opportunities in Asia Pacific to generate diverse, globally accepted clinical trial data, and much more.
-
In this webinar, gain insight into the latest regulatory and clinical developments in the field of oncology in China.
-
This webinar discusses the expansion of International Market for Ensartini and RNAi Therapeutics in Oncology, from Skin Cancers to Liver Cancers.
-
Discover how the clinical research bridge between China and the US supports accelerated clinical development from early to late phase trials while ensuring the inclusion of MRCT data packages in future regulatory applications.
-
China now represents 60% of clinical development in CAR-T therapy development globally: what have we learned to date and where are future opportunities?
FEATURED REPORTS
-
Gain valuable insights into the current state of cell and gene therapy clinical trials and the opportunities and challenges in this rapidly evolving field.
-
Discover how a well-designed and robust preclinical development plan can help identify potential safety and efficacy issues early in the drug development process, ultimately reducing the risk of failure in clinical trials.
-
Learn about the incidence, distribution, and possible control of idiopathic pulmonary fibrosis (IPF) in the Asia Pacific region, in addition to the standard of care, current trial landscape, and more.
-
Gain a better understanding of the incidence, distribution, and possible control of Alzheimer’s disease (AD) in the Asia Pacific region, the standard of care, the trial landscape, and more.
-
Gain a better understanding of the incidence, distribution, and possible control of rheumatoid arthritis (RA) in the Asia Pacific region, the standard of care, the trial landscape, and more.
-
Gain a better understanding of the incidence, distribution, and possible control of acute myeloid leukemia (AML) in the Asia Pacific region, the standard of care, the trial landscape, and more.
-
Better understand the incidence, distribution, and possible control of prostate cancer (PCa) in the Asia Pacific region, the standard of care, the trial landscape, and more.
-
Better understand the incidence, distribution, and possible control of breast cancer in the Asia Pacific region, the standard of care, the trial landscape, and more.
-
Better understand the incidence, distribution, and possible control of melanoma in the Asia Pacific region, the standard of care, the trial landscape, and more.
-
Better understand the incidence, distribution, and possible control of ovarian cancer (OC) in the Asia Pacific region, the standard of care, the trial landscape, and more.
-
China is leading the world in oncology and CAR-T research. And with over a billion people and a government friendly to biotech, it’s an ideal location for international clinical trials.
-
Global clinical trials in the Asia-Pacific region are becoming an attractive solution for young biotech companies looking to utilize their capital efficiently and secure high-quality clinical data quickly.
-
Opting to take your biotech program global can help save crucial resources, produce high-quality clinical data for your therapy, and leverage unique regional advantages like region-specific indication strategies.
-
In the coming years, the global burden of Parkinson's Disease (PD) is expected to rise. The number of people with PD in Asia is anticipated to exceed 6 million by 2030. Discover the factors leading to this in this report.
-
In December 2019, a novel coronavirus was discovered in China causing severe acute respiratory syndrome-like pneumonia which resulted in a pandemic. Find out more details regarding its spread in this report.
-
Read more about how the large population and lower volume of studies decreases competing trial risk in this region with a great need for novel drug therapies for solid tumors in Asian patients
-
Psoriasis can have a significant psychological effect on both the patient and their family. Explore the cultural factors, socioeconomic factors, and higher levels of social stigma and prejudice resulting that make this disease more prevalent in Asia.
-
DLBCL is the most prevalent Non-Hodgkin Lymphoma (NHL) which accounts for about 30%-40% of all NHL cases worldwide. Explore its prevalence in the Asia Pacific region in this report.
-
Clostridium difficile infection is one of the leading causes of morbidity and mortality worldwide. Find out more about this disease in Asia, where a mean overall prevalence of nearly 15.0% was found among hospital patients.
-
Even though NAFLD (non-alcoholic fatty liver disease) is a significant public health burden in the United States and Europe, learn why Asia has a NAFLD burden that is increasing faster than the developed countries of the West.
-
Find out how the incidence and prevalence of Ulcerative Colitis in Asia has rapidly increased over the past four decades with an incidence rate of around 6 cases per 100,000 population.
CONTACT INFORMATION
Novotech
235 Pyrmont Street, Level 3
Pyrmont, NSW 2009
AUSTRALIA
NEWS
- Novotech Acquires European CRO – Strengthens Global Operations
- Novotech Acquires US-based Drug Development Consulting Firm, CBR International: Expands Drug Development And FDA Regulatory Expertise
- Novotech Presented With Cell & Gene Excellence Award 2022 At 6th Cell & Gene Therapy World Asia Conference
FEATURED SOLUTIONS
CASE STUDIES
- From Phase I In Australia To A Global Phase III
- Study Launches Early Phase In Australia With Later Expansion To China
- Expert Consulting & Intelligent MRCT Strategy Rescues Oncology Program
- A Nimble And Flexible Solution To Rescuing An Observational Study
WHITE PAPERS
-
Learn about the global clinical trial landscape of RNA therapy, with emphasis on trends in the Asia Pacific, and recent advancements in the field.
-
Discover key trends in global Phase I trials, including highlights from the top therapeutic areas, indications, and biologic drug types in the last five-year period in popular trial regions of Asia Pacific, the United States, and Europe.
-
Learn about the global clinical trial landscape of multi-specific monoclonal antibodies (Mabs), with emphasis on trends in the Asia Pacific, and recent advancements in the field.
-
Get an overview of the global approval landscape, pathways to approval, including typical impediments to success, and the importance of formulating a robust clinical development program as made possible with the help of an experienced and well-resourced CRO.
-
Get a glimpse of the global clinical trial landscape of antibody drug conjugates (ADCs) and their trends in the Asia Pacific.
-
C3 Glomerulopathy (C3G) is a complex, rare complement-mediated renal disease. Find out its effects in the Asia Pacific.
-
Diabetic Retinopathy (DR) is the leading cause of vision loss in working-age populations, and one of the main complications of Diabetes Mellitus (DM). Read about the effects of this disease.
-
The world is heavily burdened by glaucoma, which is the second-leading cause of blindness and the primary cause of irreversible blindness. Learn about its effects in the Asia Pacific.
-
Explore the differences between the common food allergies in Asia and the West, specifically the peanut allergy.
-
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare condition that affects the ability of hematopoietic stem cells and their cellular offspring to bind specific proteins to the cell surface.
-
Explore why the Asia-Pacific region has emerged as a clinical trial hub due to the ease of regulatory compliance, low trial costs, rising patient population, and the availability of top clinical institutions as trial locations
-
Discover how a new class of therapeutics called cell and gene therapies are revolutionizing how diseases are treated and even potentially cured.
-
In this white paper, learn why western biopharma companies should take advantage of China’s revamped regulatory framework.
-
Real world evidence (RWE) can contribute valuable information to new medicine registrations, in particular, for diseases that are difficult to assess in randomized clinical trials (RCTs) and for emerging technologies.
-
Next generation sequencing (NGS) refers to a technology that detects genomic variation that is present at birth or emerges later in life. This report describes the availability of NGS in a selection of locations.
-
In this white paper, gain insight into how the Asia Pacific region, with its rapid growth of clinical trials, presents a great opportunity for conducting clinical research and has become the preferred destination for DCTs.
-
Learn how the Asia Pacific has shown significant increase in Immuno-oncology (IO) trials between 2017 and 2021 and contributes to about 35% of clinical development in IO globally.
-
Delve into how China is now more aligned with international standards, enabling biotech firms to streamline processes and timelines, which has significantly recharged biotech innovation.
-
With changing global clinical trials landscape, explore how APAC is emerging as the hot spot for conducting clinical trials, especially in China.